HSP90AA1 and breast carcinoma: Subsequently, SNX-2112 was discovered, guided by computational chemistry and crystal structures, which showed excellent affinity for HSP90 with IC50 of 3.0 nM (Table 3).423 And its oral form (SNX-5422) also entered into clinical trials (Table 2), due to delaying growth excellent antiproliferative activity in an HT-29 mouse model.424 Currently, multiple phase I clinical trials related to SNX-5422 have been completed, involved in many tumors including HER2+ breast cancer, refractory solid tumor malignancies and lymphomas.